NEW DELHI: Zydus Cadila today announced that its has received restricted emergency use approval from the Drugs Controller General of India (DCGI) V.G.
Somani for the use of ‘Virafin’, a pegylated interferon alpha-2b (PegIFN), to treat moderate covid-19 infection in adults.The drug was originally used in treatment against hepatitis B and C, and is administered in a single dose subcutaneous regimen.The company said that when administered early on during covid-19, Virafin can help patients recover faster and avoid much of the complications.